Edgemont Partners

“TMS is growing at nearly eight percent a year”

“on course to exceed a half a billion dollars by 2030”

“Esketamine and ketamine treatments are already worth an estimated $1.5 and $3.5 billion respectively”

“of the 21 million Americans living with depression, only 12.8 million seek treatment”

“6.7 million do not respond to drug treatment, of whom 5.4 million are considered eligible for TMS or Esketamine”